DexCom, Inc. (NASDAQ:DXCM) Short Interest Update

DexCom, Inc. (NASDAQ:DXCM) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 9,550,000 shares, a growth of 11.7% from the September 15th total of 8,550,000 shares. Based on an average daily trading volume, of 5,640,000 shares, the short-interest ratio is presently 1.7 days.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the sale, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,824 shares of company stock worth $126,390. Company insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after acquiring an additional 136,282 shares during the period. Blair William & Co. IL grew its holdings in shares of DexCom by 1.4% during the first quarter. Blair William & Co. IL now owns 4,532,687 shares of the medical device company’s stock worth $628,684,000 after buying an additional 64,683 shares in the last quarter. Legal & General Group Plc raised its position in shares of DexCom by 1.7% in the second quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after buying an additional 49,076 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after buying an additional 353,019 shares during the period. Finally, 1832 Asset Management L.P. boosted its holdings in shares of DexCom by 1.1% during the first quarter. 1832 Asset Management L.P. now owns 1,823,400 shares of the medical device company’s stock worth $252,906,000 after purchasing an additional 20,400 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Stock Performance

Shares of DXCM traded down $0.19 during mid-day trading on Thursday, hitting $69.71. 248,036 shares of the company’s stock were exchanged, compared to its average volume of 3,812,003. The firm has a market capitalization of $27.72 billion, a P/E ratio of 45.10, a P/E/G ratio of 2.16 and a beta of 1.18. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business’s 50 day moving average is $69.95 and its two-hundred day moving average is $101.15. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the prior year, the business earned $0.34 earnings per share. The company’s quarterly revenue was up 15.3% compared to the same quarter last year. On average, equities analysts expect that DexCom will post 1.69 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. UBS Group cut their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. BTIG Research lowered their target price on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Wells Fargo & Company reduced their price objective on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. Finally, Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $110.73.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.